FDA Highlights AI-Enabled Health Care
Per the notice below, the United States Food and Drug Administration (FDA) is highlighting the use of artificial intelligence (AI) in health care.
Digital Health Blog: A Lifecycle Management Approach toward Delivering Safe, Effective AI-enabled Health Care
As global interest in artificial intelligence (AI) in health care soars, it’s crucial to ensure the safety and effectiveness of AI-enabled medical devices, as well as their trustworthiness, fairness, and performance. A new blog post, written by Troy Tazbaz, Director, Digital Health Center of Excellence (DHCoE), and John Nicol, PhD, Digital Health Specialist, DHCoE, both of the Center for Devices and Radiological Health, U.S. Food and Drug Administration, explores these issues in the context of AI in health care settings. Our new blog post focuses on the potential of Lifecycle Management (LCM) concepts to address the unique challenges of generative AI in health care, toward helping to ensure these systems meet real-world needs while managing their inherent risks across the software lifecycle.
.png?sfvrsn=4447de7f_1)
